SCHEMBL18313530

SCHEMBL18313530

C/C(O)=C(/C)c1ccc(-c2nc3ccccn3c2NC(C)(C)C)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 2/20 0.77
ADRA1B P35368 1/20 0.74
HDAC4 P56524 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59
BACE1 P56817 4/20 0.58
BACE2 Q9Y5Z0 4/20 0.58
BRD4 O60885 1/20 0.58
TRIM24 O15164 1/20 0.53
SALL4 Q9UJQ4 1/20 0.53
TRIM33 Q9UPN9 1/20 0.53
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
MAPT P10636 2/20 0.50
NTRK1 P04629 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25416714 0.87 ADRA1B (0.91) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL25414843 0.86 ADRA1B (1.00) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL18313471 0.81 MAPT (0.77) TOP2AADRA1BBACE1BRD4ALDH1A1
SCHEMBL28600538 0.81 ADRA1B (0.80) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL16424708 0.81 ADRA1B (0.80) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL6643374 0.78 ADRA1B (0.74) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL18313625 0.78 TUBB4A (0.79) BRD4TRIM24TRIM33ALDH1A1KDM4E
SCHEMBL27101733 0.74 ADRA1B (0.67) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL6646005 0.74 ADRA1B (0.76) TOP2AADRA1BHDAC4HDAC7HDAC9
SCHEMBL2992178 0.74 ADRA1B (0.60) TOP2AADRA1BHDAC4HDAC7HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016201370-A1 COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-15 WO disclosed